Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage an ...More

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla's performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market. ...Less

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth qua ...More

Cipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This contrasts with Rs 1,222 crore reported in the same period last year. The company's Board has recommended a final dividend of Rs 13 per share for the fiscal year ending March 2026. ...Less

Domestic equities rallied for a second day on Thursday, with banks, metals and pharma powering gains even ...More

Domestic equities rallied for a second day on Thursday, with banks, metals and pharma powering gains even as IT lagged, while several major stocks saw sharp moves on earnings and announcements. ...Less

The Board has also recommended the payment of a final dividend of Rs 8.50 per equity share for the financ ...More

The Board has also recommended the payment of a final dividend of Rs 8.50 per equity share for the financial year ended March 2023. ...Less

The total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the com ...More

The total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quarter. ...Less

Cipla's North America sales, which constitute primarily US, grew 11.8% YoY to Rs 1875 crore driven by key ...More

Cipla's North America sales, which constitute primarily US, grew 11.8% YoY to Rs 1875 crore driven by key products Lanreotide (used for treating growth hormone disorder) gaining market share to 20.8% and 12-13% Albuterol (anti-asthma inhalation) coupled with robust demand in base business. ...Less

Cipla Q4 Results: Revenue from operations increased 7% year-on-year to Rs 6,163 crore in the March quarte ...More

Cipla Q4 Results: Revenue from operations increased 7% year-on-year to Rs 6,163 crore in the March quarter. EBITDA for the quarter under review increased 13% year-on-year to Rs 1,316 crore as against 1166 crore in the last year period. ...Less

Cipla Q4 Results: The company’s revenue from operations grew by 8.45% year-on-year to Rs 6,597.72 crore, ...More

Cipla Q4 Results: The company’s revenue from operations grew by 8.45% year-on-year to Rs 6,597.72 crore, compared to Rs 6,082.37 crore in the corresponding quarter of the previous fiscal ...Less

Pharma firms are expected to report double-digit rise in bottomline figures. ...More

Pharma firms are expected to report double-digit rise in bottomline figures. ...Less

In Q4, North America delivered strong growth of 41 per cent YoY and 38 per cent QoQ. ...More

In Q4, North America delivered strong growth of 41 per cent YoY and 38 per cent QoQ. ...Less

The company’s consolidated revenues for the quarter rose 5.2 per cent on-year to Rs. 4,606.45 crore, whic ...More

The company’s consolidated revenues for the quarter rose 5.2 per cent on-year to Rs. 4,606.45 crore, which was also sharply below Street’s estimate. ...Less

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of th ...More

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales. ...Less

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter comp ...More

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter compared to ₹2,139 crore in Q4FY25, while net interest income (NII) declined marginally by 0.41% sequentially from ₹6,051 crore in the same period. ...Less

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volu ...More

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volumes and flat revenues, while net profit could drop up to 5%. Cipla may report 3-6% revenue growth and a 4-5.7% rise in net profit. ...Less

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacte ...More

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Revenue remained flat at Rs 7,074 crore, with EBITDA also declining. The company plans upcoming launches to offset revenue decline and drive future growth. ...Less

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 n ...More

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 net profit to ₹565 crore despite a 12% rise in revenue. Sequentially, PAT dropped 50%, while segment performance showed mixed trends. ...Less

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, E ...More

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results. ...Less